Pediatrix Medical Group, Inc. (MD) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal a generally positive outlook, with a raised EBITDA outlook, strong NICU growth, and improved cash flow. While revenue decreased, same-unit revenue grew, and expenses were managed effectively. The Q&A section highlighted successful arbitration and stable margins, though management's vague responses on Medicaid expansion introduce some uncertainty. Overall, the raised guidance, strong financial performance, and strategic focus on partnerships suggest a positive stock price movement, likely within the 2% to 8% range.
Key Financial Performance
Adjusted EBITDA $73 million, exceeded expectations. This was driven by same unit revenue growth of over 6%, strong hospital-based volume with NICU days up 6%, favorable reimbursement factors, higher acuity levels, strong RCM collections, and increased hospital administrative fees.
Consolidated Revenue Decreased by just over 7% year-over-year, driven by non-same unit activity which declined by about $63 million, primarily due to portfolio restructuring activity. This was partially offset by strong same-unit growth of over 6%.
Same Unit Pricing Increased by 3.5% year-over-year, driven by increased patient acuity, primarily in neonatology, strong RCM cash collections, and an increase in contract administrative fees.
Same-Unit Patient Service Volumes Increased by approximately 3% year-over-year, driven by strong increases in hospital-based services, primarily neonatology (NICU days up over 6%), and modest increase in maternal fetal medicine services.
Practice-Level SW&B Expenses Declined year-over-year due to portfolio restructuring activity. However, on a same-unit basis, expenses increased due to higher incentive compensation based on practice results and salary increases (salary growth averaged 3% to 3.5%).
G&A Expense Decreased slightly year-over-year, primarily due to a net decrease in salary expense from staffing reductions across shared services completed in the prior year, and modest decreases in professional services and legal fees. These were partially offset by an increase in incentive compensation expense based on overall company financial results.
D&A Expense Declined to $5.3 million from $8.8 million in the prior year, primarily reflecting the impacts of practice dispositions.
Other Nonoperating Expense Decreased to $4.9 million from $10 million in the prior year, primarily due to an increase in interest income on cash balances and a decrease in interest expense on modestly lower average borrowings at slightly lower rates.
Operating Cash Flow Increased to $138 million from $109 million in the prior year, driven by higher earnings and increases in cash flow from deferred taxes and accounts payable and accrued expenses.
Cash Balance Ended the quarter at $225 million, with net debt of just over $380 million. This reflects net leverage of just above 1.5x using the midpoint of the updated adjusted EBITDA outlook range for 2025.
Accounts Receivable DSO At June 30, 46.4 days, down about 1.2 days from March 31 and December 31, and down over 3 days year-over-year, primarily due to improved cash collections at existing units.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue and EBITDA Performance: Adjusted EBITDA of over $73 million exceeded expectations, driven by same-unit revenue growth of over 6%. Consolidated revenue decreased by 7% due to portfolio restructuring, but same-unit pricing increased by 3.5%.
Cost Management: Ongoing cost management initiatives controlled salary trends, with practice-level SW&B expenses declining year-over-year. G&A expenses also decreased due to staffing reductions and lower professional services costs.
Cash Flow and Debt: Operating cash flow increased to $138 million, with a cash balance of $225 million and net debt of $380 million. Net leverage is at 1.5x, and cash balance is expected to reach $350-$400 million by year-end.
Operational Enhancements: Improved cash collections and automation in revenue cycle management (RCM) have been successful, reducing accounts receivable DSO by over 3 days year-over-year.
Focus on Quality and Partnerships: The company is focusing on being the best partner to hospitals and employer of choice for clinicians, emphasizing quality care in neonatology and maternal fetal medicine.
Legislative Engagement: Pediatrix is engaging with legislators on the Neonatal Care Transparency Act and advocating for the extension of premium tax credits.
Leadership Addition: Greg Neeb has been added to the team to enhance financial and operational opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Portfolio Restructuring Impact: The company's consolidated revenue decreased by over 7%, primarily due to non-same unit activity declining by $63 million, which is linked to portfolio restructuring activities. This restructuring could pose challenges in maintaining revenue stability.
Salary and Incentive Compensation Costs: Same-unit salary expenses increased due to higher incentive compensation and salary growth, which could pressure margins if not managed effectively.
Regulatory and Legislative Risks: The introduction of the Neonatal Care Transparency Act and the potential expiration of premium tax credits at the end of the year could create regulatory and financial uncertainties for the company.
Economic and Market Conditions: The company operates in a turbulent hospital-based healthcare environment, which could impact its operations and financial performance.
Debt and Financial Leverage: The company has net debt of over $380 million, which, while manageable, could limit financial flexibility in adverse conditions.
Dependence on Hospital Partnerships: The company's success is closely tied to its ability to maintain strong partnerships with hospitals, which could be a risk if these relationships weaken.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year Adjusted EBITDA Range: The company has raised and narrowed its full year adjusted EBITDA range to $245 million to $255 million, reflecting strong second quarter results and visibility into the second half of the year.
Cash Balance Outlook: The company expects its cash balance to be around $350 million to $400 million by the end of 2025, driven by higher earnings and improved cash flow.
Second Half 2025 Adjusted EBITDA: Adjusted EBITDA for the second half of 2025 is expected to be fairly ratable across the third and fourth quarters.
Revenue Growth: Top-line revenue growth achieved during the second quarter has contributed to the updated 2025 outlook range.
Legislative Impact: The company believes it can effectively manage the impact of the Neonatal Care Transparency Act, which phases in over time and has varying effects depending on state expansion status.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: The CEO, Mark S. Ordan, mentioned the possibility of employing corporate finance strategies, including share repurchases, as part of their flexibility due to a strong cash balance sheet. However, no specific details or commitments were provided.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the hospital admin fees? What percent of the pricing growth in the second quarter came from admin fees? How are these negotiations going, and how should we think about these admin fees heading into 2026?
A:Hospital admin fees were expected to be flattish in late 2024. In Q1, same unit growth was about 10% of pricing, and in Q2, admin fees made up about 1/3 of pricing growth. Negotiations involve targeting key programs and working with hospital partners to demonstrate value. While challenging, there has been some success.
Q:If you increase your admin fee by 1%, what is the flow-through to doctor compensation versus corporate, and what is the timing of this flow-through?
A:Approximately 30% to 40% of the increase flows through to doctor compensation, and the flow-through is pretty immediate.
Q:What is driving the 6% NICU growth this quarter? Is it due to a large number of babies, market share, or other factors?
A:The growth is driven by multiple factors, including increased acuity. There is no single driver, but overall, NICU growth is strong in every regard.
Q:How would the Medicaid expansion in the Big Beautiful Bill impact your operations, particularly in expansion states?
A:The impact is unclear as details of the bill's implementation are not yet announced. However, 60% of the company's volume is in non-expansion states, and the bill specifically carves out pregnant women. The company is hopeful and confident that it won't be significantly targeted.
Q:Can you elaborate on your buyback strategy and the pace of buybacks?
A:The company values a strong balance sheet for flexibility during turbulent times. While not hoarding cash, they are cautious about debt levels and acquisitions. They are prepared to buy back shares if it aligns with their strategy and leverage levels.
Q:What is the update on IDR and arbitration with payers? Are plans paying you?
A:The process has gone well for the company, and they have done well in arbitration. They remain overwhelmingly in-network, and in cases where they were out-of-network, payers have wanted them back in-network.
Q:If you annualize the first half numbers, you reach the lower end of your guidance range. Considering normal seasonality, why not raise the guidance range? Are there potential headwinds, and what is the outlook for margins?
A:The company raised guidance last quarter based on Q1 and Q2 performance. Comps get tougher in the back half of the year, which is why guidance wasn't raised further. Margins are expected to remain stable through the end of 2025.
Q:What is your contracting discussion with hospitals like, given the regulatory and reimbursement changes? Are hospitals looking to contract their service lines?
A:Hospitals are not retreating from contracting service lines. The company provides necessary services that are vital to hospital financials and patient outcomes. They are also exploring partnerships with growing hospital systems.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific impact of the Medicaid expansion in the Big Beautiful Bill, citing unclear details and implementation specifics. They used vague language like 'hope' and 'confidence' without providing concrete data or plans.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AG Research
Administrative Officer
Bank AG
CEO Executive
CFO Ordan
Chairman Moore
Chief Administrative
Conference Instructions
Division Philip
Division Tao
ET Ladies
EVP General
Executive Chairman
Executive VP
Factors press
General Chief
General Secretary
Inc Rossi
LLC Research
Leerink Partners
Officer today
Research Division
account
acuity
cash collection
decrease
expense impact
incentive compensation
increase incentive
interest
salary
MD Transcript
Pediatrix Medical Group, Inc. (MD) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call reveals mixed financial performance: revenue increased by 5%, but operating and net income decreased due to higher costs. EBITDA remained flat, while cash flow improved. The absence of strategic discussions and the risk acknowledgment in forward-looking statements indicate uncertainty. These mixed signals suggest a neutral stock price movement over the next two weeks.
Pediatrix Medical Group, Inc. (MD) Q4 2025 Earnings Call Transcript
Unknown2-19
The earnings report presents mixed signals. While the company shows operational strengths like improved cash collections and a share buyback program, it faces challenges with declining NICU volumes and increased G&A expenses. The Q&A section reveals uncertainties in M&A contributions and flat pricing assumptions, which could dampen growth expectations. Despite positive elements like technological advancements and operational strengthening, the overall sentiment remains neutral due to these offsetting factors.
Pediatrix Medical Group, Inc. (MD) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call highlights strong adjusted EBITDA, effective cost management, and a positive cash flow. Despite a year-over-year revenue decline, same-unit growth and pricing improvements are strong. The company has also been actively repurchasing shares, which is generally positive for stock price. The Q&A revealed a focus on low debt and strategic acquisitions, though some responses lacked specificity. Overall, the financial health and strategic moves suggest a positive outlook for the stock price in the short term.
Pediatrix Medical Group, Inc. (MD) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A reveal a generally positive outlook, with a raised EBITDA outlook, strong NICU growth, and improved cash flow. While revenue decreased, same-unit revenue grew, and expenses were managed effectively. The Q&A section highlighted successful arbitration and stable margins, though management's vague responses on Medicaid expansion introduce some uncertainty. Overall, the raised guidance, strong financial performance, and strategic focus on partnerships suggest a positive stock price movement, likely within the 2% to 8% range.
MD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
